Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Identification of Marine Biotechnology Value Chains with High Potential in the Northern Mediterranean Region.
Rotter A, Giannakourou A, Argente García JE, Quero GM, Auregan C, Triantaphyllidis G, Venetsanopoulou A, De Carolis R, Efstratiou C, Aboal M, Abad MÁE, Grigalionyte-Bembič E, Kotzamanis Y, Kovač M, Ljubić Čmelar M, Luna GM, Aguilera C, Acién Fernández FG, Gómez Pinchetti JL, Manzo S, Milašinčić I, Nadarmija A, Parrella L, Pinat M, Roussos E, Ruel C, Salvatori E, Sánchez Vázquez FJ, Semitiel García M, Skarmeta Gómez AF, Ulčar J, Chiavetta C. Rotter A, et al. Among authors: ruel c. Mar Drugs. 2023 Jul 22;21(7):416. doi: 10.3390/md21070416. Mar Drugs. 2023. PMID: 37504947 Free PMC article.
Safety and Efficacy of Oxaliplatin Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Colorectal and Appendiceal Cancer with Peritoneal Metastases: Results of a Multicenter Phase I Trial in the USA.
Raoof M, Whelan RL, Sullivan KM, Ruel C, Frankel PH, Cole SE, Tinsley R, Eng M, Fakih M, Chao J, Lim D, Woo Y, Paz IB, Lew M, Cristea M, Rodriguez-Rodriguez L, Fong Y, Thomas RM, Chang S, Deperalta D, Merchea A, Dellinger TH. Raoof M, et al. Among authors: ruel c. Ann Surg Oncol. 2023 Nov;30(12):7814-7824. doi: 10.1245/s10434-023-13941-2. Epub 2023 Jul 27. Ann Surg Oncol. 2023. PMID: 37501051 Free PMC article. Clinical Trial.
Immunogenicity and efficacy of pembrolizumab and doxorubicin in a phase I trial for patients with metastatic triple-negative breast cancer.
Egelston CA, Guo W, Yost SE, Ge X, Lee JS, Frankel PH, Cui Y, Ruel C, Schmolze D, Murga M, Tang A, Martinez N, Karimi M, Somlo G, Lee PP, Waisman JR, Yuan Y. Egelston CA, et al. Among authors: ruel c. Cancer Immunol Immunother. 2023 Sep;72(9):3013-3027. doi: 10.1007/s00262-023-03470-y. Epub 2023 Jun 9. Cancer Immunol Immunother. 2023. PMID: 37294342 Free PMC article. Clinical Trial.
Phase I Trial of Ipatasertib Plus Carboplatin, Carboplatin/Paclitaxel, or Capecitabine and Atezolizumab in Metastatic Triple-Negative Breast Cancer.
Yuan Y, Yost SE, Cui Y, Ruel C, Murga M, Tang A, Martinez N, Schmolze D, Waisman J, Patel N, Vora L, Tumyan L, Bozoghlanian M, Stewart D, Frankel PH. Yuan Y, et al. Among authors: ruel c. Oncologist. 2023 Jul 5;28(7):e498-e507. doi: 10.1093/oncolo/oyad026. Oncologist. 2023. PMID: 37023705 Free PMC article. Clinical Trial.
Phase 2 prospective open label study of neoadjuvant nab-paclitaxel, trastuzumab, and pertuzumab in patients with HER2-positive primary breast cancer.
Lavasani SM, Somlo G, Yost SE, Frankel PH, Ruel C, Cui Y, Murga M, Tang A, Martinez N, Kruper L, Tumyan L, Schmolze D, Yeon C, Yuan Y, Waisman JR, Mortimer J. Lavasani SM, et al. Among authors: ruel c. Cancer. 2023 Mar 1;129(5):740-749. doi: 10.1002/cncr.34589. Epub 2022 Dec 14. Cancer. 2023. PMID: 36517940 Free PMC article. Clinical Trial.
Phase II Study Combining Pembrolizumab with Aromatase Inhibitor in Patients with Metastatic Hormone Receptor Positive Breast Cancer.
Ge X, Yost SE, Lee JS, Frankel PH, Ruel C, Cui Y, Murga M, Tang A, Martinez N, Chung S, Yeon C, Stewart D, Li D, Rajurkar S, Somlo G, Mortimer J, Waisman J, Yuan Y. Ge X, et al. Among authors: ruel c. Cancers (Basel). 2022 Sep 1;14(17):4279. doi: 10.3390/cancers14174279. Cancers (Basel). 2022. PMID: 36077811 Free PMC article.
Long-Term Outcomes of Patients on a Phase II Prospective Trial of Oligometastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation and External Beam Radiation.
Hao C, Ladbury C, Lyou Y, Manoukian S, Ruel C, Frankel P, Dorff T, Wong J, Pal S, Twardowski P, Dandapani S. Hao C, et al. Among authors: ruel c. Int J Radiat Oncol Biol Phys. 2022 Nov 15;114(4):705-710. doi: 10.1016/j.ijrobp.2022.06.085. Epub 2022 Jul 5. Int J Radiat Oncol Biol Phys. 2022. PMID: 35803445 Review.
Phase I/II trial of palbociclib, pembrolizumab and letrozole in patients with hormone receptor-positive metastatic breast cancer.
Yuan Y, Lee JS, Yost SE, Frankel PH, Ruel C, Egelston CA, Guo W, Padam S, Tang A, Martinez N, Schmolze D, Presant C, Ebrahimi B, Yeon C, Sedrak M, Patel N, Portnow J, Lee P, Mortimer J. Yuan Y, et al. Among authors: ruel c. Eur J Cancer. 2021 Sep;154:11-20. doi: 10.1016/j.ejca.2021.05.035. Epub 2021 Jul 1. Eur J Cancer. 2021. PMID: 34217908 Free PMC article. Clinical Trial.
49 results